

CURRICULUM VITAE

Dr. Fabio Blandini

Luogo e data di nascita:

Cittadinanza: italiana

Stato civile:

Posizione attuale: **Dirigente Medico, con incarico di responsabile di Unità Complessa per il Coordinamento e Sviluppo della Ricerca Neurobiologica** dell'IRCCS Istituto Neurologico Nazionale "C. Mondino", Pavia

Indirizzo: IRCCS Istituto Neurologico Nazionale "C. Mondino"

27100 PAVIA

STUDI

1980-1986 Laurea in Medicina e Chirurgia, Università di Messina
1986-1990 Specializzazione in Neurologia, Università di Messina
1997-2001 Specializzazione in Biochimica e Chimica Clinica, Università di Pavia

TRAINING / INCARICHI PROFESSIONALI

1993-1995 *Post-Doctoral Fellow*, laboratori sperimentali Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA.
1995-2009 *Responsabile del Laboratorio di Neurochimica Funzionale* dell'Istituto Neurologico "C. Mondino".
1999-2000 *Visiting Professor*, laboratori sperimentali Department of Neurology, Emory University, Atlanta, GA, USA.
Dal 2004 Responsabile, per la Direzione Scientifica, della programmazione e gestione dei progetti di ricerca internazionali dell'IRCCS "C. Mondino"
Dal 2007 Responsabile del *Centro di Ricerca Interdipartimentale per la Malattia di Parkinson (CRIMP)* dell'IRCCS C. Mondino
2008 *Visiting Professor* presso il Pittsburgh Institute for Neurodegenerative Diseases (PIND), University of Pittsburgh, Pittsburgh, PA, USA
2008-2009 Consulente dell'IRCCS Neurolesi Bonino-Pulejo (Messina), per conto dell'IRCCS C. Mondino, per la progettazione dei laboratori di ricerca di neurologia sperimentale
Dal 2009 Responsabile del *Coordinamento e Sviluppo della Ricerca Neurobiologica* dell'IRCCS C. Mondino, con incarico di responsabile di Unità Semplice trasformata, nel 2013, in Unità Complessa
Dal 2011 Responsabile del *Center for Research in Neurodegenerative Diseases (CRND)* dell'IRCCS C. Mondino

- Nomina esperto *Agenzia Italiana del Farmaco* (AIFA)
 Nomina esperto *European Medicines Agency* (EMA)
- Dal 2012 Membro Action Group on Experimental Models for Neurodegenerative Diseases del JPND (*EU Joint Programme on Neurodegenerative Disease Research*)
- Dal 2013 Membro *ex officio* del Comitato Etico IRCCS Mondino – IRCCS S. Raffaele Milano, in qualità di sostituto permanente del Direttore Scientifico dell'IRCCS Mondino
- Dal 2014 Membro della Direzione Tecnico-Scientifica della Rete IRCCS/DI per l'Europa (Ministero della Salute)
- Dal 2015 Membro del Comitato Tecnico-Scientifico dell'IRCCS C. Mondino

oo

ATTIVITA' DIDATTICA

- Dal 1996 *Professore a contratto*, Scuola di Specializzazione in Neurologia (Tecniche Biochimiche)
- 2005-2011 Docente del Master Universitario di II livello “VALUTAZIONE E CONTROLLO DEL RISCHIO TOSSICOLOGICO DA INQUINANTI AMBIENTALI”, Università di Pavia
- Dal 2010 *Professore a contratto* di Neuropatologia, corso di Laurea Specialistica in Neurobiologia, Università di Pavia

oo

Abilitazione scientifica nazionale al ruolo di Professore associato nel settore concorsuale 06/D6, *Neurologia* (bando 2012)

Abilitazione scientifica nazionale al ruolo di Professore associato nel settore concorsuale 05/G1 *Farmacologia, Farmacologia Clinica e Farmacognosia* (bando 2012)

oo

Associazioni Professionali

- Società Italiana di Neuroscienze (SINS) (*membro del consiglio direttivo dal 2012 al 2015*)
 Society for Neuroscience (SFN)
 Lega Italiana Morbo di Parkinson e malattie Extrapiramidali (LIMPE)

Attività editoriali

Membro dell'editorial board delle seguenti riviste internazionali indicizzate: 1) *Neurobiology of Disease*; 2) *Frontiers in Cellular Neuroscience*; 3) *Frontiers in Neuroanatomy*; 4) *Functional Neurology*

Grant reviewer per i seguenti enti nazionali ed internazionali (ultimi 5 anni):

- European Research Council (Commissione Europea)
- FRC – Fédération pour la Recherche sur le Cerveau (Francia)
- Fonds National de la Recherche Luxembourg:
 - a) *Multi-annual Thematic Research Program (CORE) applications;*

- b) *AFR (Aides à la Formation-Recherche) applications to support PhD and postdoctoral researchers;*
- c) *applications to support co-funding for the organisation of exploratory workshops in Luxembourg (Research Communication Scheme)*
- Medical Research Council (UK): *Neurosciences & Mental Health Board grant proposals*
- Ministero dell'Università e della Ricerca: *valutazione progetti assegni di ricerca*
- Regione Sardegna: *bando annuale "Promozione della Ricerca Scientifica e della innovazione tecnologica in Sardegna"*

ATTIVITA' DI RICERCA

Neurobiologia e Neurofarmacologia, con particolare riferimento allo studio della patogenesi, fisiopatologia, bio-marcatori e terapie innovative della malattia di Parkinson. L'attività di ricerca del Dr. Blandini si articola principalmente in due macroaree: 1) *ricerca di base (modelli sperimentali di malattia)*; 2) *ricerca pre-clinica e clinica nel paziente*.

Perfetta conoscenza della lingua inglese, scritta e parlata (full professional proficiency)

oo

PARTECIPAZIONE A PROGETTI DI RICERCA NAZIONALI ED INTERNAZIONALI

Ministero della Salute – Ricerca Finalizzata

- *Ruolo di aree specifiche dei nuclei della base (n. subtalamico) e tronco-encefaliche (locus coeruleus) nell'epilessia sperimentale (2002-2003) – Ruolo nel progetto: Coordinatore nazionale*
- *Correlati neurobiologici, neurofisiologici, genetici e clinici delle discinesie da l-dopa nella malattia di Parkinson (2003-2004) – Ruolo nel progetto: Coordinatore nazionale*
- *I determinanti molecolari del parkinsonismo come substrato di strategie terapeutiche innovative (2003-2004) – Ruolo nel progetto: responsabile Unità IRCCS Mondino*
- *Correlazioni clinico-biologiche nella Malattia di Parkinson mediante l'utilizzo di modelli animali e cellulari di pazienti (2004-2005) – Ruolo nel progetto: responsabile Unità IRCCS Mondino (Coordinamento: IRCCS Don Gnocchi, Milano)*
- *Studio delle alterazioni metaboliche coinvolte nel processo neurodegenerativo responsabile della malattia di Parkinson (2004-2005) – Ruolo nel progetto: responsabile Unità IRCCS Mondino (Coordinamento: Regione Piemonte)*
- *La plasticità neuronale nell'evoluzione della malattia di Parkinson e nella risposta al trattamento: studio multi-integrato mirato all'individuazione di nuovi protocolli diagnostico-terapeutici (2004-2005) – Ruolo nel progetto: responsabile Unità IRCCS Mondino (prog. ex art.56; Coordinamento: IRCCS C. Mondino)*
- *Ruolo dei meccanismi di eccitotossicità nello sviluppo del danno nigrostriatale in un modello animale di malattia di Parkinson (2005-2006) – Ruolo nel progetto: responsabile Unità IRCCS Mondino (prog. ex art.56; Coordinamento: Istituto Superiore di Sanità')*
- *Danno neuronale e strategie neuroriparative cellulari nella malattia di Parkinson (2005-2006) – Ruolo nel progetto: responsabile Unità IRCCS Mondino prog. ex art.56; Coordinamento: IRCCS C. Mondino)*

- *Eccitotossicità e neuroinfiammazione in un modello sperimentale di malattia di Parkinson: ruolo dei recettori metabotropici per il glutammato* (2006-2007) – Ruolo nel progetto: responsabile Unità IRCCS Mondino (prog. ex art.56; Coordinamento: IRCCS Neuromed, Pozzilli)
- *Dai meccanismi patogenetici agli indicatori di malattia ed allo sviluppo di procedure terapeutiche e gestionali nella Malattia di Parkinson* (2008-2009) – Ruolo nel progetto: responsabile Unità IRCCS Mondino (Coordinamento: IRCCS S. Lucia, Roma)
- *Caratterizzazione ed utilizzo di cellule staminali pluripotenti ottenute da fibroblasti riprogrammati di pazienti con malattie neurodegenerative* (2009-2011 prog. Giovani ricercatori) – Ruolo nel progetto: responsabile Unità IRCCS Mondino (Coordinamento: IRCCS S. Raffaele, Milano)

Ministero della Salute – Ricerca Corrente

Dal 2008 il dott. Blandini è responsabile della Linea 3 di Ricerca Corrente dell'IRCCS C. Mondino (MALATTIE NEURODEGENERATIVE E DISORDINI DEL MOVIMENTO).

Ministero Università' e Ricerca

- *FIRB (2004-2007): I recettori metabotropici per il glutammato come target terapeutico nella neurodegenerazione associata ai disturbi del movimento* – Ruolo nel progetto: responsabile Unità IRCCS Mondino (Coordinamento: Università' di Pisa)
- *PRIN (2011-2013): Neurochemical and neuroanatomical substrates of gastrointestinal dysfunction in experimental Parkinson's disease* – Ruolo nel progetto: partecipante (Coordinamento: Università' di Pisa)

Fondazione CARIPLO

- *Modelling Parkinson's disease by iPS technology: generation of human affected dopaminergic neurons and analysis of their molecular and physiological pathogenic bases* (2009-2011) – Ruolo nel progetto: Co-PI (Coordinamento: IRCCS S. Raffaele, Milano)
- *Role of innate immunity in the neuroprotective effect of estrogens: molecular mechanisms and implications for Parkinson's disease* (2012-2014) – Ruolo nel progetto: Co-PI (Coordinamento: IRCCS Mondino)
- *Dopaminergic modulation of CD4+ T lymphocytes: relevance for neurodegeneration and neuroprotection in Parkinson's disease - the dopaminergic neuro-immune connection* (2012-2015) – Ruolo nel progetto: Co-PI (Coordinamento: Università dell'Insubria)

RICERCA INTERNAZIONALE

VI Programma Quadro UE

2004-2007: *Migraine genes and neurobiological pathways* (**EUROHEAD**; coordinamento: University of Leiden, The Netherlands); ruolo nel progetto: partecipante

2007-2011: *Functional genomics and neurobiology of epilepsy: a basis for new therapeutic strategies* (**EPICURE**; Coordinamento: IRCCS C. Besta, Milano); ruolo nel progetto: partecipante

VII Programma Quadro UE

2008-2010: *Continuous monitoring of medication overuse headache in Europe and Latin America: development and standardization of an alert and decision support system (COMOESTAS; Coordinamento: IRCCS C. Mondino); ruolo nel progetto: partecipante*

2008-2011: *A Brain-Chip Interface for High-resolution Bi-directional Communication (CYBERAT; Coordinamento: Università di Padova); ruolo nel progetto: third party*

ERANET (Joint Transnational Call)

2008-2011: *Synthesis and validation of antiparkinsonian drugs targeting GPCR heteromers (HETEROPARK; Coordinamento: University of Barcelona); ruolo nel progetto: partecipante*

COEN (Centres of Excellence in Neurodegeneration)

2012-2013: *Mitochondrial dysfunction and susceptibility to Parkinson's disease: new models of pathogenetic interactions - first call; leader: DZNE, Bonn. Ruolo nel progetto: coordinatore unità italiana (IRCCS Mondino)*

2013-2015: *Targeting glucocerebrosidase for disease-modifying treatments in Parkinson's disease - Centres of Excellence in Neurodegeneration - second call; leader: MRC-UCL, London. Ruolo nel progetto: coordinatore unità italiana (IRCCS Mondino)*

JPND (EU Joint Programme – Neurodegenerative Disease Research)

2016-2018: *GBA1 mutations in Parkinson disease: clinical and biochemical prodrome, risk profile and pathogenetic modelling for therapeutic intervention (GBA-PARK). Leader: MRC-UCL, London. Ruolo nel progetto: coordinatore unità italiana (IRCCS Mondino)*

Michael J. Fox Foundation (USA)

2015-2016: *Modulation of Transferrin Receptor 2 to halt iron overload in dopaminergic neurons” (Target validation call). Coordinatore: Erasmus Medical Center, Rotterdam. Ruolo nel progetto: coordinatore unità italiana (IRCCS Mondino)*

oo

Bibliografia

Autore di 134 pubblicazioni indicizzate su riviste internazionali (fonte: PubMed)
H-index: 31 (fonte: Web of Science)

Pavia, 20/7/2016



Dr. Fabio Blandini

Fabio Blandini - ELENCO PUBBLICAZIONI (PubMed 20/7/2016)

1. Pellegrini C, Fornai M, Colucci R, Tirotta E, **Blandini F**, Levandis G, Cerri S, Segnani C, Ippolito C, Bernardini N, Cseri K, Blandizzi C, Haskó G, Antonioli L. Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration. *J Neuroinflammation*. 2016 Jun 13;13(1):146. doi: 10.1186/s12974-016-0608-5. PubMed [citation] PMID: 27295950, PMCID: PMC4907252
2. Sepe S, Milanese C, Gabriels S, Derks KW, Payan-Gomez C, van IJcken WF, Rijksen YM, Nigg AL, Moreno S, Cerri S, **Blandini F**, Hoeijmakers JH, Mastroberardino PG. Inefficient DNA Repair Is an Aging-Related Modifier of Parkinson's Disease. *Cell Rep*. 2016 May 31;15(9):1866-75. doi: 10.1016/j.celrep.2016.04.071. Epub 2016 May 19. PubMed [citation] PMID: 27210754, PMCID: PMC4893155
3. Find NL, Terlizzi R, Munksgaard SB, Bendtsen L, Tassorelli C, Nappi G, Katsarava Z, Lainez M, Goicochea MT, Shand B, Fadic R, Spadafora S, Pagani M, Jensen R; COMOESTAS Consortium. Medication overuse headache in Europe and Latin America: general demographic and clinical characteristics, referral pathways and national distribution of painkillers in a descriptive, multinational, multicenter study. *J Headache Pain*. 2015 Dec;17(1):20. doi: 10.1186/s10194-016-0612-2. Epub 2016 Mar 8. PubMed [citation] PMID: 26957090, PMCID: PMC4783306
4. Feligioni M, Mango D, Piccinin S, Imbriani P, Iannuzzi F, Caruso A, De Angelis F, **Blandini F**, Mercuri NB, Pisani A, Nisticò R. Subtle alterations of excitatory transmission are linked to presynaptic changes in the hippocampus of PINK1-deficient mice. *Synapse*. 2016 Jun;70(6):223-30. doi: 10.1002/syn.21894. Epub 2016 Feb 29. PubMed [citation] PMID: 26850695
5. Fornai M, Pellegrini C, Antonioli L, Segnani C, Ippolito C, Barocelli E, Ballabeni V, Vegezzi G, Al Harraq Z, **Blandini F**, Levandis G, Cerri S, Blandizzi C, Bernardini N, Colucci R. Enteric Dysfunctions in Experimental Parkinson's Disease: Alterations of Excitatory Cholinergic Neurotransmission Regulating Colonic Motility in Rats. *J Pharmacol Exp Ther*. 2016 Feb;356(2):434-44. doi: 10.1124/jpet.115.228510. Epub 2015 Nov 18. PubMed [citation] PMID: 26582732
6. Mastroberardino PG, Ambrosi G, **Blandini F**, Milanese C, Sepe S. Fibroblasts from skin biopsies as a tool for biomarker discovery in Parkinson's disease. *Free Radic Biol Med*. 2014 Oct;75 Suppl 1:S10. doi:

cell loss and synergistically modulates L-DOPA-induced rotational behavior in a rodent model of Parkinson's disease. *J Neurochem*. 2015 Aug;134(4):740-7. doi: 10.1111/jnc.13162. Epub 2015 Jun 4. PubMed [citation] PMID: 25962878

13. Ferrigno A, Vairetti M, Ambrosi G, Rizzo V, Richelmi P, **Blandini F**, Fuzzati-Armentero MT. Selective blockade of mGlu5 metabotropic glutamate receptors is protective against hepatic mitochondrial dysfunction in 6-OHDA lesioned Parkinsonian rats. *Clin Exp Pharmacol Physiol*. 2015 Jun;42(6):695-703. doi: 10.1111/1440-1681.12410. PubMed [citation] PMID: 25904005

14. Greco R, Tassorelli C, Mangione AS, Levandis G, Certo M, Nappi G, Bagetta G, **Blandini F**, Amantea D. Neuroprotection by the PARP inhibitor PJ34 modulates cerebral and circulating RAGE levels in rats exposed to focal brain ischemia. *Eur J Pharmacol*. 2014 Dec 5;744:91-7. doi: 10.1016/j.ejphar.2014.10.006. Epub 2014 Oct 15. PubMed [citation] PMID: 25446913

15. Vegezzi G, Al Harraq Z, Levandis G, Cerri S, **Blandini F**, Gnudi G, Miduri F, Blandizzi C, Domenichini G, Bertoni S, Ballabeni V, Barocelli E. Radiological analysis of gastrointestinal dysmotility in a model of central nervous dopaminergic degeneration: comparative study with conventional in vivo techniques in the rat. *J Pharmacol Toxicol Methods*. 2014 Sep-Oct;70(2):163-9. doi: 10.1016/j.vascn.2014.08.003. Epub 2014 Aug 10. PubMed [citation] PMID: 25117630

16. Ambrosi G, Ghezzi C, Sepe S, Milanese C, Payan-Gomez C, Bombardieri CR, Armentero MT, Zangaglia R, Pacchetti C, Mastroberardino PG, **Blandini F**. Bioenergetic and proteolytic defects in fibroblasts from patients with sporadic Parkinson's disease. *Biochim Biophys Acta*. 2014 Sep;1842(9):1385-94. doi: 10.1016/j.bbadis.2014.05.008. Epub 2014 May 20. PubMed [citation] PMID: 24854107

17. Nisticò R, Ferraina C, Marconi V, **Blandini F**, Negri L, Egebjerg J, Feligioni M. Age-related changes of protein SUMOylation balance in the A β PP Tg2576 mouse model of Alzheimer's disease. *Front Pharmacol*. 2014;5:63. doi: 10.3389/fphar.2014.00063. PubMed [citation] PMID: 24778618, PMCID: PMC3985012

18. Cerri S, Levandis G, Ambrosi G, Montepeloso E, Antoninetti GF, Franco R, Lanciego JL, Baqi Y, Müller CE, Pinna A, **Blandini F**, Armentero MT. Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease. *J Neuropathol Exp Neurol*. 2014 May;73(5):414-24. doi: 10.1097/NEN.000000000000064. PubMed [citation] PMID: 24709676

19. Mango D, Barbato G, Piccirilli S, Panico MB, Feligioni M, Schepisi C, Graziani M, Porrini V, Benarese M, Lanzillotta A, Pizzi M, Pieraccini S, Sironi M, Blandini F, Nicoletti F, Mercuri NB, Imbimbo BP, Nisticò R. Electrophysiological and metabolic effects of CHF5074 in the hippocampus: protection against in vitro ischemia. *Pharmacol Res.* 2014 Mar;81:83-90. doi: 10.1016/j.phrs.2014.02.010. Epub 2014 Mar 12. PubMed [citation] PMID: 24630950

20. Diana V, Libani IV, Armentero MT, **Blandini F**, Lucignani G, Silani V, Cova L, Ottobriani L. A reliable indirect cell-labelling protocol for optical imaging allows ex vivo visualisation of mesenchymal stem cells after transplantation. *Arch Ital Biol.* 2013 Sep;151(3):114-25. doi: 10.4449/aib.v151i3.1463. PubMed [citation] PMID: 24599629

21. Ambrosi G, Cerri S, **Blandini F**. A further update on the role of excitotoxicity in the pathogenesis of Parkinson's disease. *J Neural Transm (Vienna).* 2014 Aug;121(8):849-59. doi: 10.1007/s00702-013-1149-z. Epub 2014 Jan 1. Review. PubMed [citation] PMID: 24380931

22. Greco R, Mangione AS, Siani F, **Blandini F**, Vairetti M, Nappi G, Sandrini G, Buzzi MG, Tassorelli C. Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia. *Cephalalgia.* 2014 Jul;34(8):594-604. doi: 10.1177/0333102413517776. Epub 2013 Dec 23. PubMed [citation] PMID: 24366981

23. **Blandini F**, Armentero MT. Dopamine receptor agonists for Parkinson's disease. *Expert Opin Investig Drugs.* 2014 Mar;23(3):387-410. doi: 10.1517/13543784.2014.869209. Epub 2013 Dec 9. Review. PubMed [citation] PMID: 24313341

24. Milani P, Ambrosi G, Gammoh O, **Blandini F**, Cereda C. SOD1 and DJ-1 converge at Nrf2 pathway: a clue for antioxidant therapeutic potential in neurodegeneration. *Oxid Med Cell Longev.* 2013;2013:836760. doi: 10.1155/2013/836760. Epub 2013 Jul 28. Review. PubMed [citation] PMID: 23983902, PMCID: PMC3745953

25. Fuzzati-Armentero MT, Ghezzi C, Nisticò R, Oda A, **Blandini F**. Single or combined treatment with L-DOPA and quinpirole differentially modulate expression and phosphorylation of key regulatory kinases in neuroblastoma cells. *Neurosci Lett.* 2013 Sep 27;552:168-73. doi: 10.1016/j.neulet.2013.07.023. Epub 2013 Jul 26. PubMed [citation] PMID: 23896526

26. **Blandini F.** From bench to bedside: the importance for neurodegenerative disorders of crosstalk between basic and clinical research. *Funct Neurol.* 2013 Jan-Mar;28(1):5. No abstract available. PubMed [citation] PMID: 23731909, PMCID: PMC3812725

27. Russo R, Ciociaro A, Berliocchi L, Cassiano MG, Rombolà L, Ragusa S, Bagetta G, **Blandini F**, Corasaniti MT. Implication of limonene and linalyl acetate in cytotoxicity induced by bergamot essential oil in human neuroblastoma cells. *Fitoterapia.* 2013 Sep;89:48-57. doi: 10.1016/j.fitote.2013.05.014. Epub 2013 May 23. PubMed [citation] PMID: 23707744

28. **Blandini F.** Neural and immune mechanisms in the pathogenesis of Parkinson's disease. *J Neuroimmune Pharmacol.* 2013 Mar;8(1):189-201. doi: 10.1007/s11481-013-9435-y. Epub 2013 Feb 3. Review. PubMed [citation] PMID: 23378275

29. Grecchi S, Mazzini G, Lisa A, Armentero MT, Bergamaschi R, Romani A, **Blandini F**, Di Perri C, Scovassi AI. Search for cellular stress biomarkers in lymphocytes from patients with multiple sclerosis: a pilot study. *PLoS One.* 2012;7(9):e44935. doi: 10.1371/journal.pone.0044935. Epub 2012 Sep 13. Erratum in: *PLoS One.* 2012;7(11):doi/10.1371/annotation/8c8710a2-bd43-4f65-b21e-69ec522c4f22. PubMed [citation] PMID: 23028690, PMCID: PMC3441649

30. Morelli M, **Blandini F**, Simola N, Hauser RA. A(2A) Receptor Antagonism and Dyskinesia in Parkinson's Disease. *Parkinsons Dis.* 2012;2012:489853. doi: 10.1155/2012/489853. Epub 2012 Jun 17. PubMed [citation] PMID: 22754707, PMCID: PMC3382949

31. Perrotta A, Arce-Leal N, Tassorelli C, Gasperi V, Sances G, **Blandini F**, Serrao M, Bolla M, Pierelli F, Nappi G, Maccarrone M, Sandrini G. Acute reduction of anandamide-hydrolase (FAAH) activity is coupled with a reduction of nociceptive pathways facilitation in medication-overuse headache subjects after withdrawal treatment. *Headache.* 2012 Oct;52(9):1350-61. doi: 10.1111/j.1526-4610.2012.02170.x. Epub 2012 Jun 1. PubMed [citation] PMID: 22670561

32. Nisticò R, Cavallucci V, Piccinin S, Macrì S, Pignatelli M, Mehdawy B, Blandini F, Laviola G, Lauro D, Mercuri NB, D'Amelio M. Insulin receptor β -subunit

haploinsufficiency impairs hippocampal late-phase LTP and recognition memory. *Neuromolecular Med.* 2012 Dec;14(4):262-9. doi: 10.1007/s12017-012-8184-z. Epub 2012 Jun 3. PubMed [citation] PMID: 22661254

33. Colucci M, Cervio M, Faniglione M, De Angelis S, Pajoro M, Levandis G, Tassorelli C, **Blandini F**, Feletti F, De Giorgio R, Dellabianca A, Tonini S, Tonini M. Intestinal dysmotility and enteric neurochemical changes in a Parkinson's disease rat model. *Auton Neurosci.* 2012 Aug 16;169(2):77-86. doi: 10.1016/j.autneu.2012.04.005. Epub 2012 May 16. PubMed [citation] PMID: 22608184

34. Ferrari M, Martignoni E, **Blandini F**, Riboldazzi G, Bono G, Marino F, Cosentino M. Association of UDP-glucuronosyltransferase 1A9 polymorphisms with adverse reactions to catechol-O-methyltransferase inhibitors in Parkinson's disease patients. *Eur J Clin Pharmacol.* 2012 Nov;68(11):1493-9. doi: 10.1007/s00228-012-1281-y. Epub 2012 Apr 15. PubMed [citation] PMID: 22527346

35. Greco R, Amantea D, Mangione AS, Petrelli F, Gentile R, Nappi G, **Blandini F**, Corasaniti MT, Tassorelli C. Modulation of RAGE isoforms expression in the brain and plasma of rats exposed to transient focal cerebral ischemia. *Neurochem Res.* 2012 Jul;37(7):1508-16. doi: 10.1007/s11064-012-0778-1. Epub 2012 Apr 19. PubMed [citation] PMID: 22528836

36. Bossolasco P, Cova L, Levandis G, Diana V, Cerri S, Lambertenghi Delilieri G, Polli E, Silani V, **Blandini F**, Armentero MT. Noninvasive near-infrared live imaging of human adult mesenchymal stem cells transplanted in a rodent model of Parkinson's disease. *Int J Nanomedicine.* 2012;7:435-47. doi: 10.2147/IJN.S27537. Epub 2012 Jan 31. PubMed [citation] PMID: 22334776, PMCID: PMC3273978

37. **Blandini F**, Armentero MT. Animal models of Parkinson's disease. *FEBS J.* 2012 Apr;279(7):1156-66. doi: 10.1111/j.1742-4658.2012.08491.x. Epub 2012 Feb 28. Review. PubMed [citation] PMID: 22251459

38. **Blandini F**, Armentero MT. New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors. *Expert Opin Investig Drugs.* 2012 Feb;21(2):153-68. doi: 10.1517/13543784.2012.651457. Epub 2012 Jan 11. Review. PubMed [citation] PMID: 22233485

39. Cova L, Bossolasco P, Armentero MT, Diana V, Zennaro E, Mellone M, Calzarossa C,

Cerri S, Deliliers GL, Polli E, **Blandini F**, Silani V. Neuroprotective effects of human mesenchymal stem cells on neural cultures exposed to 6-hydroxydopamine: implications for reparative therapy in Parkinson's disease. *Apoptosis*. 2012 Mar;17(3):289-304. doi: 10.1007/s10495-011-0679-9. PubMed [citation] PMID: 22160861

40. Vairetti M, Ferrigno A, Rizzo V, Ambrosi G, Bianchi A, Richelmi P, **Blandini F**, Armentero MT. Impaired hepatic function and central dopaminergic denervation in a rodent model of Parkinson's disease: a self-perpetuating crosstalk? *Biochim Biophys Acta*. 2012 Feb;1822(2):176-84. doi: 10.1016/j.bbadis.2011.11.008. Epub 2011 Nov 15. PubMed [citation] PMID: 22119596

41. Berliocchi L, Ciociaro A, Russo R, Cassiano MG, **Blandini F**, Rotiroti D, Morrone LA, Corasaniti MT. Toxic profile of bergamot essential oil on survival and proliferation of SH-SY5Y neuroblastoma cells. *Food Chem Toxicol*. 2011 Nov;49(11):2780-92. doi: 10.1016/j.fct.2011.08.017. Epub 2011 Aug 22. PubMed [citation] PMID: 21878361

42. Armentero MT, Levandis G, Bazzini E, Cerri S, Ghezzi C, **Blandini F**. Adhesion molecules as potential targets for neuroprotection in a rodent model of Parkinson's disease. *Neurobiol Dis*. 2011 Sep;43(3):663-8. doi: 10.1016/j.nbd.2011.05.017. Epub 2011 Jun 12. PubMed [citation] PMID: 21684338

43. Melcangi RC, Caruso D, Levandis G, Abbiati F, Armentero MT, **Blandini F**. Modifications of neuroactive steroid levels in an experimental model of nigrostriatal degeneration: potential relevance to the pathophysiology of Parkinson's disease. *J Mol Neurosci*. 2012 Jan;46(1):177-83. doi: 10.1007/s12031-011-9570-y. Epub 2011 Jun 14. PubMed [citation] PMID: 21671084

44. Munksgaard SB, Allena M, Tassorelli C, Rossi P, Katsarava Z, Bendtsen L, Nappi G, Jensen R; Comoestas Consortium. What do the patients with medication overuse headache expect from treatment and what are the preferred sources of information? *J Headache Pain*. 2011 Feb;12(1):91-6. doi: 10.1007/s10194-011-0298-4. Epub 2011 Feb 20. PubMed [citation] PMID: 21336966, PMCID: PMC3055992

45. **Blandini F**. An update on the potential role of excitotoxicity in the pathogenesis of Parkinson's disease. *Funct Neurol*. 2010 Apr-Jun;25(2):65-71. PubMed [citation] PMID: 20923603

46. Fazi B, Biancolella M, Mehdawy B, Corazzari M, Minella D, **Blandini F**, Moreno S, Nardacci R, Nisticò R, Sepe S, Novelli G, Piacentini M, Di Sano F. Characterization of gene expression induced by RTN-1C in human neuroblastoma cells and in mouse brain. *Neurobiol Dis.* 2010 Dec;40(3):634-44. doi: 10.1016/j.nbd.2010.08.007. Epub 2010 Aug 12. PubMed [citation] PMID: 20708685
47. Cappuccio I, Colapicchioni C, Santangelo V, Sale P, **Blandini F**, Bonelli M, Niccolini C, Busceti C, Bucci D, Nicoletti F, Melchiorri D. The origin recognition complex subunit, ORC3, is developmentally regulated and supports the expression of biochemical markers of neuronal maturation in cultured cerebellar granule cells. *Brain Res.* 2010 Oct 28;1358:1-10. doi: 10.1016/j.brainres.2010.07.052. Epub 2010 Jul 29. PubMed [citation] PMID: 20674557
48. Colleoni S, Galli C, Giannelli SG, Armentero MT, **Blandini F**, Broccoli V, Lazzari G. Long-term culture and differentiation of CNS precursors derived from anterior human neural rosettes following exposure to ventralizing factors. *Exp Cell Res.* 2010 Apr 15;316(7):1148-58. doi: 10.1016/j.yexcr.2010.02.013. Epub 2010 Feb 17. PubMed [citation] PMID: 20171210
49. Armentero MT, Sinforiani E, Ghezzi C, Bazzini E, Levandis G, Ambrosi G, Zangaglia R, Pacchetti C, Cereda C, Cova E, Basso E, Celi D, Martignoni E, Nappi G, **Blandini F**. Peripheral expression of key regulatory kinases in Alzheimer's disease and Parkinson's disease. *Neurobiol Aging.* 2011 Dec;32(12):2142-51. doi: 10.1016/j.neurobiolaging.2010.01.004. Epub 2010 Jan 27. PubMed [citation] PMID: 20106550
50. Ambrosi G, Armentero MT, Levandis G, Bramanti P, Nappi G, **Blandini F**. Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease. *Brain Res Bull.* 2010 Apr 29;82(1-2):29-38. doi: 10.1016/j.brainresbull.2010.01.011. Epub 2010 Jan 25. PubMed [citation] PMID: 20100549
51. Cova L, Armentero MT, Zennaro E, Calzarossa C, Bossolasco P, Busca G, Lambertenghi Delilieri G, Polli E, Nappi G, Silani V, **Blandini F**. Multiple neurogenic and neurorescue effects of human mesenchymal stem cell after transplantation in an experimental model of Parkinson's disease. *Brain Res.* 2010 Jan 22;1311:12-27. doi: 10.1016/j.brainres.2009.11.041. Epub 2009 Nov 26. PubMed

[citation] PMID: 19945443

52. **Blandini F**, Cova L, Armentero MT, Zennaro E, Levandis G, Bossolasco P, Calzarossa C, Mellone M, Giuseppe B, Deliliers GL, Polli E, Nappi G, Silani V. Transplantation of undifferentiated human mesenchymal stem cells protects against 6-hydroxydopamine neurotoxicity in the rat. *Cell Transplant*. 2010;19(2):203-17. doi: 10.3727/096368909X479839. Epub 2009 Nov 10. PubMed [citation] PMID: 19906332

53. **Blandini F**, Balestra B, Levandis G, Cervio M, Greco R, Tassorelli C, Colucci M, Faniglione M, Bazzini E, Nappi G, Clavenzani P, Vigneri S, De Giorgio R, Tonini M. Functional and neurochemical changes of the gastrointestinal tract in a rodent model of Parkinson's disease. *Neurosci Lett*. 2009 Dec 31;467(3):203-7. doi: 10.1016/j.neulet.2009.10.035. Epub 2009 Oct 14. PubMed [citation] PMID: 19835930

54. Rossi P, Jensen R, Nappi G, Allena M; COMOESTAS Consortium. A narrative review on the management of medication overuse headache: the steep road from experience to evidence. *J Headache Pain*. 2009 Dec;10(6):407-17. doi: 10.1007/s10194-009-0159-6. Epub 2009 Oct 3. Review. Erratum in: *J Headache Pain*. 2010 Feb;11(1):85. PubMed [citation] PMID: 19802522, PMCID: PMC3476213

55. Allena M, Katsarava Z, Nappi G; COMOESTAS Consortium. From drug-induced headache to medication overuse headache. A short epidemiological review, with a focus on Latin American countries. *J Headache Pain*. 2009 Apr;10(2):71-6. doi: 10.1007/s10194-009-0101-y. Epub 2009 Feb 24. Review. PubMed [citation] PMID: 19238511, PMCID: PMC3451648

56. **Blandini F**, Bazzini E, Marino F, Saporiti F, Armentero MT, Pacchetti C, Zangaglia R, Martignoni E, Lecchini S, Nappi G, Cosentino M. Calcium homeostasis is dysregulated in parkinsonian patients with L-DOPA-induced dyskinesias. *Clin Neuropharmacol*. 2009 May-Jun;32(3):133-9. doi: 10.1097/WNF.0B013E3181761466. PubMed [citation] PMID: 18978486

57. Greco R, Tassorelli C, Armentero MT, Sandrini G, Nappi G, **Blandini F**. Role of central dopaminergic circuitry in pain processing and nitroglycerin-induced hyperalgesia. *Brain Res*. 2008 Oct 31;1238:215-23. doi: 10.1016/j.brainres.2008.08.022. Epub 2008 Aug 16. PubMed [citation] PMID: 18761334

58. **Blandini F**, Armentero MT, Martignoni E. The 6-hydroxydopamine model: news from

the past. *Parkinsonism Relat Disord*. 2008;14 Suppl 2:S124-9. doi: 10.1016/j.parkreldis.2008.04.015. Epub 2008 Jul 2. Review. PubMed [citation] PMID: 18595767

59. Armentero MT, Levandis G, Bramanti P, Nappi G, **Blandini F**. Dietary restriction does not prevent nigrostriatal degeneration in the 6-hydroxydopamine model of Parkinson's disease. *Exp Neurol*. 2008 Aug;212(2):548-51. doi: 10.1016/j.expneurol.2008.04.006. Epub 2008 Apr 15. PubMed [citation] PMID: 18508049

60. Giorgi FS, **Blandini F**, Cantafora E, Biagioni F, Armentero MT, Pasquali L, Orzi F, Murri L, Paparelli A, Fornai F. Activation of brain metabolism and fos during limbic seizures: the role of locus coeruleus. *Neurobiol Dis*. 2008 Jun;30(3):388-99. doi: 10.1016/j.nbd.2008.02.008. Epub 2008 Mar 6. PubMed [citation] PMID: 18395460

61. Levandis G, Bazzini E, Armentero MT, Nappi G, **Blandini F**. Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. *Neurobiol Dis*. 2008 Jan;29(1):161-8. Epub 2007 Sep 1. PubMed [citation] PMID: 17933546

62. Tassorelli C, Armentero MT, Greco R, Fancellu R, Sandrini G, Nappi G, **Blandini F**. Behavioral responses and Fos activation following painful stimuli in a rodent model of Parkinson's disease. *Brain Res*. 2007 Oct 24;1176:53-61. Epub 2007 Aug 14. PubMed [citation] PMID: 17884026

63. Frenzilli G, Ferrucci M, Giorgi FS, **Blandini F**, Nigro M, Ruggieri S, Murri L, Paparelli A, Fornai F. DNA fragmentation and oxidative stress in the hippocampal formation: a bridge between 3,4-methylenedioxymethamphetamine (ecstasy) intake and long-lasting behavioral alterations. *Behav Pharmacol*. 2007 Sep;18(5-6):471-81. PubMed [citation] PMID: 17762515

64. Tassorelli C, Greco R, Armentero MT, **Blandini F**, Sandrini G, Nappi G. A role for brain cyclooxygenase-2 and prostaglandin-E2 in migraine: effects of nitroglycerin. *Int Rev Neurobiol*. 2007;82:373-82. PubMed [citation] PMID: 17678972

65. Greco R, Amantea D, **Blandini F**, Nappi G, Bagetta G, Corasaniti MT, Tassorelli C. Neuroprotective effect of nitroglycerin in a rodent model of ischemic stroke:

evaluation of Bcl-2 expression. *Int Rev Neurobiol.* 2007;82:423-35. PubMed [citation] PMID: 17678976

66. Bazzini E, Samuele A, Granelli M, Levandis G, Armentero MT, Nappi G, **Blandini F**. Proteasomal inhibition and apoptosis regulatory changes in human isolated lymphocytes: the synergistic role of dopamine. *J Cell Biochem.* 2008 Feb 15;103(3):877-85. PubMed [citation] PMID: 17647258

67. Rango M, Arighi A, Biondetti P, Barberis B, Bonifati C, **Blandini F**, Pacchetti C, Martignoni E, Bresolin N, Nappi G. Magnetic resonance spectroscopy in Parkinson's disease and parkinsonian syndromes. *Funct Neurol.* 2007 Apr-Jun;22(2):75-9. Review. PubMed [citation] PMID: 17637209

68. Martignoni E, Tassorelli C, Nappi G, Zangaglia R, Pacchetti C, **Blandini F**. Homocysteine and Parkinson's disease: a dangerous liaison? *J Neurol Sci.* 2007 Jun 15;257(1-2):31-7. Epub 2007 Mar 1. Review. PubMed [citation] PMID: 17336337

69. **Blandini F**, Levandis G, Bazzini E, Nappi G, Armentero MT. Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model. *Eur J Neurosci.* 2007 Jan;25(2):397-405. PubMed [citation] PMID: 17284180

70. Giorgi FS, Mauceli G, **Blandini F**, Ruggieri S, Paparelli A, Murri L, Fornai F. Locus coeruleus and neuronal plasticity in a model of focal limbic epilepsy. *Epilepsia.* 2006;47 Suppl 5:21-5. PubMed [citation] PMID: 17239101

71. Tamburini I, **Blandini F**, Gesi M, Frenzilli G, Nigro M, Giusiani M, Paparelli A, Fornai F. MDMA induces caspase-3 activation in the limbic system but not in striatum. *Ann N Y Acad Sci.* 2006 Aug;1074:377-81. PubMed [citation] PMID: 17105935

72. Armentero MT, Levandis G, Nappi G, Bazzini E, **Blandini F**. Peripheral inflammation and neuroprotection: systemic pretreatment with complete Freund's adjuvant reduces 6-hydroxydopamine toxicity in a rodent model of Parkinson's disease. *Neurobiol Dis.* 2006 Dec;24(3):492-505. Epub 2006 Oct 3. PubMed [citation] PMID: 17023164

73. Castoldi AF, **Blandini F**, Randine G, Samuele A, Manzo L, Coccini T. Brain

monoaminergic neurotransmission parameters in weanling rats after perinatal exposure to methylmercury and 2,2',4,4',5,5'-hexachlorobiphenyl (PCB153). *Brain Res.* 2006 Sep 27;1112(1):91-8. Epub 2006 Aug 10. PubMed [citation] PMID: 16904659

74. **Blandini F**, Fancellu R, Armentero MT, Tassorelli C, Greco R, Fornai F, Nappi G. Unilateral lesion of the subthalamic nucleus enhances cortical fos expression associated with focally evoked seizures in the rat. *Brain Res.* 2006 Jul 26;1101(1):145-50. Epub 2006 Jun 19. PubMed [citation] PMID: 16782074

75. **Blandini F**, Armentero MT, Tassorelli C, Greco R, Fancellu R, Bramanti P, Nappi G, Martignoni E. Selective lesion of the substantia nigra pars reticulata reduces the cortical Fos expression induced by stimulation of striatal D1-like receptors, in the rat. *Exp Neurol.* 2006 Jul;200(1):240-4. Epub 2006 Mar 6. PubMed [citation] PMID: 16516888

76. **Blandini F**, Sinforiani E, Pacchetti C, Samuele A, Bazzini E, Zangaglia R, Nappi G, Martignoni E. Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease. *Neurology.* 2006 Feb 28;66(4):529-34. PubMed [citation] PMID: 16505307

77. **Blandini F**, Rinaldi L, Tassorelli C, Sances G, Motta M, Samuele A, Fancellu R, Nappi G, Leon A. Peripheral levels of BDNF and NGF in primary headaches. *Cephalalgia.* 2006 Feb;26(2):136-42. PubMed [citation] PMID: 16426267

78. Armentero MT, Fancellu R, Nappi G, Bramanti P, **Blandini F**. Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease. *Neurobiol Dis.* 2006 Apr;22(1):1-9. Epub 2005 Nov 11. PubMed [citation] PMID: 16289868

79. Samuele A, Mangiagalli A, Armentero MT, Fancellu R, Bazzini E, Vairetti M, Ferrigno A, Richelmi P, Nappi G, **Blandini F**. Oxidative stress and pro-apoptotic conditions in a rodent model of Wilson's disease. *Biochim Biophys Acta.* 2005 Sep 25;1741(3):325-30. PubMed [citation] PMID: 16081251

80. **Blandini F**. Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease? *CNS Drug Rev.* 2005 Summer;11(2):183-94. Review. PubMed [citation] PMID: 16007239

81. Trotti R, Carratelli M, Bo P, Barbieri M, Mangiagalli A, Samuele A, Gabanti E, **Blandini F**. Pro-oxidant activity and methionine metabolism in chronic alcohol abusers: relationship to alcohol withdrawal and folate administration. *Panminerva Med.* 2004 Sep;46(3):161-4. PubMed [citation] PMID: 15510084
82. **Blandini F**, Cosentino M, Mangiagalli A, Marino F, Samuele A, Rasini E, Fancellu R, Tassorelli C, Pacchetti C, Martignoni E, Riboldazzi G, Calandrella D, Lecchini S, Frigo G, Nappi G. Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson's disease. The effect of dopaminergic treatment. *J Neural Transm (Vienna)*. 2004 Aug;111(8):1017-30. Epub 2004 Mar 19. PubMed [citation] PMID: 15254790
83. Bono G, Fancellu R, **Blandini F**, Santoro G, Mauri M. Cognitive and affective status in mild hypothyroidism and interactions with L-thyroxine treatment. *Acta Neurol Scand.* 2004 Jul;110(1):59-66. PubMed [citation] PMID: 15180808
84. **Blandini F**, Armentero MT, Fancellu R, Blaugrund E, Nappi G. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. *Exp Neurol.* 2004 Jun;187(2):455-9. PubMed [citation] PMID: 15144871
85. Cosentino M, Rasini E, Colombo C, Marino F, **Blandini F**, Ferrari M, Samuele A, Lecchini S, Nappi G, Frigo G. Dopaminergic modulation of oxidative stress and apoptosis in human peripheral blood lymphocytes: evidence for a D1-like receptor-dependent protective effect. *Free Radic Biol Med.* 2004 May 15;36(10):1233-40. PubMed [citation] PMID: 15110388
86. Mangiagalli A, Samuele A, Armentero MT, Bazzini E, Nappi G, **Blandini F**. Effects of homocysteine on apoptosis-related proteins and anti-oxidant systems in isolated human lymphocytes. *Eur J Biochem.* 2004 May;271(9):1671-6. PubMed [citation] PMID: 15096206
87. Tassorelli C, **Blandini F**, Greco R, Nappi G. Nitroglycerin enhances cGMP expression in specific neuronal and cerebrovascular structures of the rat brain. *J Chem Neuroanat.* 2004 Mar;27(1):23-32. PubMed [citation] PMID: 15036360
88. **Blandini F**, Mangiagalli A, Cosentino M, Marino F, Samuele A, Rasini E, Fancellu R, Martignoni E, Riboldazzi G, Calandrella D, Frigo GM, Nappi G. Peripheral markers of apoptosis in Parkinson's disease: the effect of dopaminergic drugs. *Ann N Y Acad Sci.* 2003 Dec;1010:675-8. PubMed [citation] PMID: 15033810

89. Colombo C, Cosentino M, Marino F, Rasini E, Ossola M, **Blandini F**, Mangiagalli A, Samuele A, Ferrari M, Bombelli R, Lecchini S, Nappi G, Frigo G. Dopaminergic modulation of apoptosis in human peripheral blood mononuclear cells: possible relevance for Parkinson's disease. *Ann N Y Acad Sci.* 2003 Dec;1010:679-82. PubMed [citation] PMID: 15033811
90. **Blandini F**. Adenosine receptors and L-DOPA-induced dyskinesia in Parkinson's disease: potential targets for a new therapeutic approach. *Exp Neurol.* 2003 Dec;184(2):556-60. Review. No abstract available. PubMed [citation] PMID: 14769348
91. **Blandini F**, Braunewell KH, Manahan-Vaughan D, Orzi F, Sarti P. Neurodegeneration and energy metabolism: from chemistry to clinics. *Cell Death Differ.* 2004 Apr;11(4):479-84. No abstract available. PubMed [citation] PMID: 14713955
92. Fornai F, Lenzi P, Frenzilli G, Gesi M, Ferrucci M, Lazzeri G, Biagioni F, Nigro M, Falleni A, Giusiani M, Pellegrini A, **Blandini F**, Ruggieri S, Paparelli A. DNA damage and ubiquitinated neuronal inclusions in the substantia nigra and striatum of mice following MDMA (ecstasy). *Psychopharmacology (Berl).* 2004 May;173(3-4):353-63. Epub 2003 Dec 13. PubMed [citation] PMID: 14673567
93. **Blandini F**, Mangiagalli A, Martignoni E, Samuele A, Fancellu R, Tassorelli C, Cosentino M, Marino F, Rasini E, Calandrella D, Riboldazzi G, Colombo C, Frigo GM, Nappi G. Effects of dopaminergic stimulation on peripheral markers of apoptosis: relevance to Parkinson's disease. *Neurol Sci.* 2003 Oct;24(3):157-8. PubMed [citation] PMID: 14598064
94. Fancellu R, Armentero MT, Nappi G, **Blandini F**. Neuroprotective effects mediated by dopamine receptor agonists against malonate-induced lesion in the rat striatum. *Neurol Sci.* 2003 Oct;24(3):180-1. PubMed [citation] PMID: 14598076
95. **Blandini F**, Greenamyre JT. Protective and symptomatic strategies for therapy of Parkinson's disease. *Drugs Today (Barc).* 1999 Jun;35(6):473-83. PubMed [citation] PMID: 12973393
96. **Blandini F**, Nappi G, Fancellu R, Mangiagalli A, Samuele A, Riboldazzi G, Calandrella D, Pacchetti C, Bono G, Martignoni E. Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with

tolcapone or entacapone in patients with Parkinson's disease. *J Neural Transm* (Vienna). 2003 Aug;110(8):911-22. PubMed [citation] PMID: 12898346

97. Memo M, **Blandini F**, Nappi G, Spano P. Neuroprotection: promise and pitfalls in anti-inflammatory treatment of Alzheimer's disease. *Funct Neurol*. 2002 Oct-Dec;17(4):175-6. No abstract available. PubMed [citation] PMID: 12675259

98. **Blandini F**, Fancellu R, Orzi F, Conti G, Greco R, Tassorelli C, Nappi G. Selective stimulation of striatal dopamine receptors of the D1- or D2-class causes opposite changes of fos expression in the rat cerebral cortex. *Eur J Neurosci*. 2003 Feb;17(4):763-70. PubMed [citation] PMID: 12603266

99. Spano P, Nappi G, Memo M, **Blandini F**. Neuronal networks in emotions. *Funct Neurol*. 2002 Jul-Sep;17(3):111-2. No abstract available. PubMed [citation] PMID: 12549713

100. **Blandini F**, Fancellu R, Orzi F, Conti G, Greco R, Tassorelli C, Nappi G. Effects of the intrastriatal administration of selective dopaminergic agonists on Fos expression in the rat brain. *Neurol Sci*. 2002 Sep;23 Suppl 2:S57-8. PubMed [citation] PMID: 12548342

101. Armentero MT, Fancellu R, Nappi G, **Blandini F**. Dopamine receptor agonists mediate neuroprotection in malonate-induced striatal lesion in the rat. *Exp Neurol*. 2002 Dec;178(2):301-5. PubMed [citation] PMID: 12504889

102. Nappi G, Spano P, **Blandini F**, Memo M. Functional neurology at the dawn of the third millennium: the translation of neuroscience into neurology. *Funct Neurol*. 2002 Jan-Mar;17(1):5-6. No abstract available. PubMed [citation] PMID: 12086113

103. Tassorelli C, **Blandini F**, Costa A, Preza E, Nappi G. Nitroglycerin-induced activation of monoaminergic transmission in the rat. *Cephalalgia*. 2002 Apr;22(3):226-32. PubMed [citation] PMID: 12047463

104. Martignoni E, **Blandini F**, Pacchetti C, Nappi G. COMT inhibition and safety. *Funct Neurol*. 2001;16(4 Suppl):135-40. Review. No abstract available. PubMed [citation] PMID: 11996508

105. **Blandini F**. The role of the subthalamic nucleus in the pathophysiology of Parkinson's disease. *Funct Neurol*. 2001;16(4 Suppl):99-106. Review. No abstract

available. PubMed [citation] PMID: 11996537

106. Conti G, **Blandini F**, Tassorelli C, Giubilei F, Fornai F, Zocchi A, Orzi F. Intrastriatal injection of D1 or D2 dopamine agonists affects glucose utilization in both the direct and indirect pathways of the rat basal ganglia. *Neurosci Lett*. 2001 Aug 31;309(3):161-4. PubMed [citation] PMID: 11514066

107. **Blandini F**, Greenamyre JT, Fancellu R, Nappi G. Blockade of subthalamic glutamatergic activity corrects changes in neuronal metabolism and motor behavior in rats with nigrostriatal lesions. *Neurol Sci*. 2001 Feb;22(1):49-50. PubMed [citation] PMID: 11487196

108. **Blandini F**, Fancellu R, Martignoni E, Mangiagalli A, Pacchetti C, Samuele A, Nappi G. Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease. *Clin Chem*. 2001 Jun;47(6):1102-4. No abstract available. PubMed [citation] PMID: 11375298

109. **Blandini F**, Nappi G, Greenamyre JT. Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease. *Ann Neurol*. 2001 Apr;49(4):525-9. PubMed [citation] PMID: 11310632

110. Tassorelli C, Costa A, **Blandini F**, Joseph SA, Nappi G. Effect of nitric oxide donors on the central nervous system--nitroglycerin studies in the rat. *Funct Neurol*. 2000;15 Suppl 3:19-27. Review. PubMed [citation] PMID: 11200790

111. Orzi F, Fornai F, **Blandini F**. Mapping neuronal activity of the basal ganglia in experimental models of Parkinson's disease: contributions of the [¹⁴C]2-deoxyglucose method. *Funct Neurol*. 2000 Oct-Dec;15(4):269-76. No abstract available. PubMed [citation] PMID: 11213530

112. **Blandini F**, Nappi G, Tassorelli C, Martignoni E. Functional changes of the basal ganglia circuitry in Parkinson's disease. *Prog Neurobiol*. 2000 Sep;62(1):63-88. Review. PubMed [citation] PMID: 10821982

113. **Blandini F**, Martignoni E, Ricotti R, di Jeso F, Nappi G. Determination of hydroxyl free radical formation in human platelets using high-performance liquid chromatography with electrochemical detection. *J Chromatogr B Biomed Sci Appl*. 1999 Sep 10;732(1):213-20. PubMed [citation] PMID: 10517238

114. Martignoni E, **Blandini F**, Godi L, Desideri S, Pacchetti C, Mancini F, Nappi G. Peripheral markers of oxidative stress in Parkinson's disease. The role of L-DOPA. *Free Radic Biol Med*. 1999 Aug;27(3-4):428-37. PubMed [citation] PMID: 10468218
115. **Blandini F**, Conti G, Martignoni E, Colangelo V, Nappi G, Di Grezia R, Orzi F. Modifications of local cerebral metabolic rates for glucose and motor behavior in rats with unilateral lesion of the subthalamic nucleus. *J Cereb Blood Flow Metab*. 1999 Feb;19(2):149-54. PubMed [citation] PMID: 10027770
116. **Blandini F**, Greenamyre JT. Prospects of glutamate antagonists in the therapy of Parkinson's disease. *Fundam Clin Pharmacol*. 1998;12(1):4-12. Review. PubMed [citation] PMID: 9523179
117. **Blandini F**, Nappi G, Greenamyre JT. Quantitative study of mitochondrial complex I in platelets of parkinsonian patients. *Mov Disord*. 1998 Jan;13(1):11-5. PubMed [citation] PMID: 9452319
118. **Blandini F**, Joseph SA, Tassorelli C. Systemic administration of ephedrine induces Fos protein expression in caudate putamen and subthalamic nucleus of rats. *Funct Neurol*. 1997 Sep-Oct;12(5):293-6. PubMed [citation] PMID: 9439947
119. **Blandini F**, Martignoni E, Pacchetti C, Desideri S, Rivellini D, Nappi G. Simultaneous determination of L-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection. *J Chromatogr B Biomed Sci Appl*. 1997 Oct 24;700(1-2):278-82. PubMed [citation] PMID: 9390741
120. **Blandini F**, Garcia-Osuna M, Greenamyre JT. Subthalamic ablation reverses changes in basal ganglia oxidative metabolism and motor response to apomorphine induced by nigrostriatal lesion in rats. *Eur J Neurosci*. 1997 Jul;9(7):1407-13. PubMed [citation] PMID: 9240398
121. **Blandini F**, Porter RH, Greenamyre JT. Glutamate and Parkinson's disease. *Mol Neurobiol*. 1996 Feb;12(1):73-94. Review. PubMed [citation] PMID: 8732541
122. **Blandini F**, Greenamyre JT, Nappi G. The role of glutamate in the pathophysiology of Parkinson's disease. *Funct Neurol*. 1996 Jan-Feb;11(1):3-15. Review. No

abstract available. PubMed [citation] PMID: 8936453

123. **Blandini F**, Greenamyre JT. Assay of [3H]dihydrorotenone binding to complex I in intact human platelets. *Anal Biochem.* 1995 Sep 1;230(1):16-9. PubMed [citation] PMID: 8585613

124. **Blandini F**, Porter RH, Greenamyre JT. Autoradiographic study of mitochondrial complex I and glutamate receptors in the basal ganglia of rats after unilateral subthalamic lesion. *Neurosci Lett.* 1995 Feb 17;186(2-3):99-102. PubMed [citation] PMID: 7777208

125. **Blandini F**, Martignoni E, Sances E, Bono G, Nappi G. Combined response of plasma and platelet catecholamines to different types of short-term stress. *Life Sci.* 1995 Feb 17;56(13):1113-20. PubMed [citation] PMID: 9001445

126. **Blandini F**, Greenamyre JT. Effect of subthalamic nucleus lesion on mitochondrial enzyme activity in rat basal ganglia. *Brain Res.* 1995 Jan 9;669(1):59-66. PubMed [citation] PMID: 7712165

127. Costa A, Martignoni E, **Blandini F**, Petraglia F, Genazzani AR, Nappi G. Effects of etoperidone on sympathetic and pituitary-adrenal responses to diverse stressors in humans. *Clin Neuropharmacol.* 1993 Apr;16(2):127-38. PubMed [citation] PMID: 8386590

128. Martignoni E, **Blandini F**, Melzi d'Eril GV, D'Andrea G, Sances G, Costa A, Nappi G. The influence of gender in the evaluation of platelet and plasma catecholamines. *Life Sci.* 1993;52(25):1995-2004. PubMed [citation] PMID: 8502129

129. **Blandini F**, Martignoni E, Melzi d'Eril GV, Biasio L, Sances G, Lucarelli C, Rizzo V, Costa A, Nappi G. Free plasma catecholamine levels in healthy subjects: a basal and dynamic study. The influence of age. *Scand J Clin Lab Invest.* 1992 Feb;52(1):9-17. PubMed [citation] PMID: 1594891

130. Martignoni E, **Blandini F**, Petraglia F, Pacchetti C, Bono G, Nappi G. Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type. *J Neural Transm Park Dis Dement Sect.* 1992;4(3):191-205. PubMed [citation] PMID: 1320891

131. Cavallini A, Micieli G, Martignoni E, **Blandini F**, Fariello R, Nappi G. Cardiopressor effects of short-term treatment with cabergoline in L-dopa stable responder parkinsonian patients: relevance of postprandial hypotension. *Clin Neuropharmacol.* 1991 Aug;14(4):343-51. PubMed [citation] PMID: 1680557
132. Martignoni E, Bono G, **Blandini F**, Sinforiani E, Merlo P, Nappi G. Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of Alzheimer type. Influence of treatment with L-deprenyl. *J Neural Transm Park Dis Dement Sect.* 1991;3(1):15-25. PubMed [citation] PMID: 1712206
133. Sances G, Martignoni E, Fioroni L, **Blandini F**, Facchinetti F, Nappi G. Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. *Headache.* 1990 Nov;30(11):705-9. PubMed [citation] PMID: 2074162
134. Nappi G, Sandrini G, Granella F, Ruiz L, Cerutti G, Facchinetti F, **Blandini F**, Manzoni GC. A new 5-HT₂ antagonist (ritanserin) in the treatment of chronic headache with depression. A double-blind study vs amitriptyline. *Headache.* 1990 Jun;30(7):439-44. PubMed [citation] PMID: 2119355